Del-Budai Centrumkorhaz Szent Imre Egyetemi Oktatokorhaz — Clinical Trial Site

17 Registered trials

1 Currently recruiting

Organisation

Del-Budai Centrumkorhaz Szent Imre Egyetemi Oktatokorhaz

Location

Budapest, Hungary

Identifier

ORG-100043649

Address

Tetenyi Ut 12-16, XI Kerulet, 1115, Hungary

Departments

Angiologia
Anyagcsere Központ
Belgyogyaszati Szakmak Matrix Szervezete, Angiologiai Profil
Cardiology
Department of Gastroenterology
Endocrinology and Metabolic Centre
Fül- Orr- és Gégészeti Profil
Fül-Orr-Gégészet
Fül-Orr-Gégészeti Profil
Gasztroenterológiai osztály
Kardiológiai Profil
Klinikai Onkológia Osztály
Klinikai Onkológiai Osztály

Clinical trials at this site (17)

Search interface

Efficacy and safety of a combined therapy in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, … Pending

2025-521985-82-00 Diabetic sensorimotor polyneuropathy (DSPN) 4
EASE SBS 5 (Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS) Recruiting

2024-512486-14-00 Short Bowel Syndrome 5 2026-01-22
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Long-term safety of apraglutide in short bowel syndrome Ended

2023-510389-28-00 short bowel syndrome 5 2021-06-14
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia –… Ended

2023-504914-31-00 Hyperlipidaemia 11 2024-11-10
Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended

2023-505712-37-00 The participants must have a histologically confirmed d 10 2024-06-06
A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure… Ended

2023-507640-36-00 Resistant hypertension (rHTN) defined as blood pressure 5 2024-04-29
A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended

2023-505499-32-00 Uncontrolled hypertension (uTHN) defined as blood press 5 2024-03-08
Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended

2023-506268-15-00 Chronic Rhinosinusitis (CRS) in Adults 5 2023-06-05
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Ended

2024-517612-29-00 acute heart failure 11 2023-02-14
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended

2024-513992-42-00 venous thromboembolism (VTE) in patients with gastroint 10 2022-09-13
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended

2023-509569-19-00 venous thromboembolism (VTE) 10 2022-08-10
A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended

2023-505476-29-00 Giant Cell Arteritis 5 2019-04-05
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended

2022-500395-57-00 Resectable high-risk Locally Advanced Cutaneous Squamou 5 2019-03-04
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5